Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin Rebate Settlement Leaves Door Open For Boston Investigation

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering-Plough's July 30 settlement with the Philadelphia U.S. Attorney does not preclude additional criminal prosecution of the company over its Medicaid "best price" reporting for Claritin

You may also be interested in...



Schering Doubles Legal Reserves To $500 Mil. For Boston Investigation

Company adds $250 mil. in litigation reserves primarily relating to the Boston U.S. Attorney’s investigation into Schering’s marketing practices. Schering also took a $9 mil. charge for facility consolidation during the second quarter.

Schering Doubles Legal Reserves To $500 Mil. For Boston Investigation

Company adds $250 mil. in litigation reserves primarily relating to the Boston U.S. Attorney’s investigation into Schering’s marketing practices. Schering also took a $9 mil. charge for facility consolidation during the second quarter.

Schering-Plough Physician Payments May Be Next Target Of Federal Prosecutors

Increasing media coverage, including a CNN interview with the Boston U.S. Attorney and the Neurontin “whistleblower,” has raised the profile of allegations that Schering offered inappropriate payments to physicians to prescribe Intron-A.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel